Perspective on RET proto-oncogene and thyroid cancer

Cancer Journal

Volumn 6, Issue 2, 2000, Pages 50-57

  Le, Hop N ^a   Norton, Jeffrey A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE MUTATION; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID CANCER;

BIOLOGICAL MARKERS; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; DROSOPHILA PROTEINS; GENETIC SCREENING; GENOTYPE; HUMANS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 0033913699     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;6:759-767.
2. Suarez HG, du Villard JA, Severino M et al. Presence of mutations in all three ras genes in human thyroid rumors. Oncogene 1990;5:565.
3. Karga H, Lee JK, Vickery ALJ et al. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 1991;73:832.
4. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990;4:1474.
5. O'Sullivan CO, Barton CM, Staddon SL et al. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinol 1991;4:345.
6. Ito T, Seyama T, Mizuno T et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369.
7. Robbins J, Merino MJ, Boice JD et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991;115:133.
8. Pasini B, Ceccherini I, Romeo G. RET mutations in human disease. Tren Genet 1996;2:138-144.
9. Josart GH, Clark OH. Well-differentiated thyroid cancer. Curr Probl Surg 1994;31:937.
10. Printice RL, Kato H, Yoshimoto K et al. Radiation exposure and thyroid cancer incidence among Hiroshima and Nagasaki residents. Natl Cancer Inst Monogr 1982;62:207.
11. Pacini F, Vorontsova T, Demidchik EP et al. A 1997 Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997;82:3564-3569.
12. Furmanchuk AW, Averkin JI, Egloff B et al. 1992 Pathomorphological findings in thyroid cancers of children from the Republic of Belarus: a study of 86 cases occurring between 1986 and 1991. Histopathology 1992;21:401-408.
13. McLeod MK, Thompson NW. Hürthle cell neoplasms of the thyroid. Otolaryngol Clin North Am 1990;23:441.
14. Saad MF, Ordonez NG, Rashid RK et al. Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients. Medicine 1984;63:319-342.
15. Moley JF. The molecular genetics of multiple endocrine neoplasia type 2A and related syndromes. Annu Rev Med 1997;48:409-420.
16. Howe JR, Norton JA, Wells SAJ. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: review of long-term follow-up. Surgery 1993;114:1070-1077.
17. Ponder BA, Smith DP. The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res 1996;70:179-222.
18. Chong GC, Beahrs OH, Sizemore GW et al. Medullary carcinoma of the thyroid gland. Cancer 1975;35:695-704.
19. Norton JA, Froome LC, Farrell RE et al. Multiple endocrine neoplasia type iib-the most aggressive form of medullary thyroid carcinoma. Surg Clin North Am 1979;59:109-118.
20. Farndon JR, Leight GS, Dilley WG et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986;73:278-281.
21. Passini B, Borrello MG, Greco A et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet 1995;10:35-40.
22. Pachnis V, Mankoo B, and Costantini F. Expression of the c-RET proto-oncogene during mouse embryogenesis. Development 1993;119:1005-1017.
23. Tsuzuki T, Takahashi M, Asai N et al. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 1995;10:191-198.
24. Anderson DJ. Molecular control of cell fate in the neural crest: the sympathoadrenal lineage. Annu Rev Neurosci 1993;16:129-158.
25. Romeo G, Ceccherini I, Celli J et al. Association of MEN 2A and Hirschsprung disease. J Intern Med 1998;243:515-520.
26. Angrist M, Bolk S, Thiel B et al. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung's disease. Hum Mol Genet 1995;4:821-830.
27. Schuchardt A, D'Agati V, Larrson-blomber L et al. The c-RET receptor tyrosine kinase gene is required for the development of the kidney and the enteric nervous system. Nature 1994;367:380-383.
28. Takahashi M, Buma Y, Iwamoto T et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988;3:571-578.
29. Mathew CGP, Chin KS, Easton DF et al. A linked generic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987;328:527-528.
30. Simpson NE, Kidd KK, Goodfellow PJ et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by generic linkage. Nature 1987;328:528-530.
31. Mulligan LM, Kwok JBJ, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460.
32. Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
33. Gardner E, Papi L, Easton DF et al. Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2. Hum Mol Genet 1993;2:241-246.
34. Donghi R, Sozzi G, Pierotti MA et al. Ret oncogene associate with human papillary thyroid carcinoma assigned to chromosome 10q11-q12 in the same region as multiple endocrine neoplasia type 2a. Oncogene 1989;4:521-523.
35. Pasini B, Hofstra RMW, Yin L et al. The physical map of the human RET proto-oncogene. 1995;11:1737-1743.
36. Schneider R. The human proto-oncogene ret: a communicative cadherin? Trends Biochem Sci 1992;17:468-469.
37. Santoro RM, Melillo F, Carolomagno R et al. Molecular biology of the MEN 2 gene. J Intern Med 1998;243:505-508.
38. Arighi E, Alberti L, Torriti F et al. Identification of Shc docking site on Ret tyrosine kinase. Oncogene 1997;14:773-782.
39. Treanor J, Goodman L, de Sauvage et al. Characterisation of a multicomponent receptor for GDNF. Nature 1996;382:80-83.
40. Klein RD, Sherman D, Ho WH et al. A GPI-linked protein that interacts with RET to form a candidate neurturin receptor. Nature 1997;387:717-721.
41. Trupp M, Raynoschek C, Belluardo N et al. Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-ret receptor tyrosine kinase. Mol Cell Neurosci 1998;11:47-63.
42. Fusco A, Grieco M, Santoro M et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987;328:170-172.
43. Kommonith P. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Virchows Arch 1997;431:1-9.
44. Grieco M, Santoro M, Berlingieri MT et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60:557-563.
45. Bongarzone I, Monzini N, Borrello MG et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine-kinase and the regulatory subunit RI alpha of cyclic AMP protein kinase A. Mol Cell Biol 1993;13:358-366.
46. Santoro M, Dathan NA, Berlingieri MT et al. Molecular characterization of RET/PTC3: a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994;9:509-516.
47. Santoro M, Melillo RM, Berlingieri MT et al. The TRK and RET tyrosine-kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Diff 1993; 4:77-84.
48. Bongarzone I, Pierotti MA, Monzini N et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989;4:1457-1462.
49. Ishizaka Y, Kobayashi S, Ushijima T et al. Detection of ret/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991;6:1667-1672.
50. Ito T, Seyama T, Iwamoto KS, et al. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 1993;53:2940-2943.
51. Bongarzone I, Fugazzola L, Vigneri P et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 1998;81:2006-2009.
52. Jhiang SM, Caruso DR, Gilmore E et al. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene 1997;7:1331-1337.
53. Sugg SL, Zheng L, Rosen IB et al. ret/PTC-1,-2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab 1996;81:3360-3365.
54. Tallini G, Santoro M, Helie M et al. RET/PTC Oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998;2:287-294.
55. Mulligan LM, Eng C, Healey CS et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994;6;70-74.
56. Takahashi M, Buma Y, Hiai H. Isolation of ret proto-oncogene on an amino-terminal signal. Oncogene 1989;4:805-806.
57. Santoro M, Carlomagno F, Romanova A et al. Activation of RET as a dominant transforming gene by germ line mutations of MEN 2A and MEN 2B. Science 1995;267:381-383.
58. Berndt I, Reuter M, Saller B et al. A new hot spot for mutations in the ret proto-oncogenes causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998;83:770-774.
59. Hofstra RM, Landsvater RM, Ceccherini I et al. A mutation in the ret proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:275-276.
60. Carlson KM, Dou S, Chi D et al. Single missense mutation in the tyrosine kinase catalytic domain of the ret proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci 1994;91:1579-1583.
61. Smith DP, Holughton C, Ponder BAJ. Germline mutation of ret codon 883 in two cases of de novo MEN 2B. Oncogene 1997;15:1213-1217.
62. Eng C, Mulligan LM, Smith DP et al. Mutation of the RET protooncogen in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 1995;12:209-212.
63. Eng C, Smith DP, Mulligan LM et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-513.
64. Kalinin V, Frilling A 27-bp deletion in the ret proto-oncogene as a somatic mutation associated with medullary thyroid carcinoma. J Mol Med 1998;76:365-367.
65. Knudson AG. Antioncogenes and human cancer. Proc Nad Acad Sci USA 1993;90:10914-10921.
66. Romei C, Elisei R, Pinchera A et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996;81:1619-1622.
67. Zedenius J, Larsson C, Bergholm U et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995;80:3088-3090.
68. Marsh DJ, Andrew SD, Eng C et al. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996;56:1241-1243.
69. Wohllk N, Cote GJ, Bugalho M et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996;81:3740-3745.
70. Eng C, Mulligan LM, Smith DP et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 1995;43:123-127.
71. Santoro M, Wong WT, Aroca P et al. An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway. Mol Cell Biol 1994;14:663-675.
72. Ponder BAJ. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 1999;59(suppl): 1736s-1742s.
73. Carlomagno F, Melillo RM, Visconti R et al. GDNF differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Endocrinology 1998;139:3613-3619.
74. Bongarzone I, Vigano E, Alberti L et al. Full activation of MEN 2B mutant RET by an additional MEN 2A mutation or by ligand GDNF stimulation. Oncogene 1998;16:2295-2301.
75. Songyang Z, Carraway KL, Eck MJ et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signaling. Nature 1995;373:536-539.
76. Schuffenecker I, Virally-Monod M, Brohet R et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the ret proto-oncogene. J Clin Endocrinol Metab 1998;83:487-491.
77. Eng C, Clayton D, Schuffenecker I et al. The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium. JAMA 1996;276:1575-1579.
78. Wells SA, Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998;106:29-34.
79. Laimore TC, Frisella MM, Wells SAJ. Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma. Ann Med 1996;28:401-406.
80. Lips CJM, Landsvater RM, Hoppener JSM et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-835.